NCT04703686View on ClinicalTrials.gov

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

January 10, 2023

Study Completion Date

March 1, 2026

Conditions
Diffuse Large B-Cell Lymphoma RefractoryRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaRefractory Primary Mediastinal Large B-Cell Cell LymphomaRefractory Mantle Cell Lymphoma
Interventions
DRUG

Obinutuzumab

1000mg - prephase - one infusion at D-3

DRUG

RO7082859

2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)

Trial Locations (15)

21034

CHU de Dijon - Hôpital le Bocage, Dijon

31059

IUCT Oncopole, Toulouse

33604

CHU de Bordeaux - Hôpital Haut Leveque, Pessac

34295

CHU Montpellier, Montpellier

35033

CHU de Rennes - Hôpital Pontchaillou, Rennes

44093

CHU Nantes, Nantes

59037

CHRU Lille - Hôpital Claude Huriez, Lille

63000

CHU de Clermont Ferrand, Clermont-Ferrand

69130

CHU Lyon Sud, Pierre-Bénite

75475

Hôpital Saint Louis, Paris

76038

Centre Henri Becquerel, Rouen

94010

Hopital Henri Mondor, Créteil

Unknown

APHP - Hôpital de la Pitiè Salpetrière, Paris

APHP - Hôpital Saint Antoine, Paris

CHU de Brabois, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

The Lymphoma Academic Research Organisation

OTHER